(NASDAQ: TSHA) Taysha Gene Therapies's forecast annual revenue growth rate of -1.07% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 65.48%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 10.37%.
Taysha Gene Therapies's revenue in 2025 is $8,333,000.On average, 2 Wall Street analysts forecast TSHA's revenue for 2025 to be $1,631,812,991, with the lowest TSHA revenue forecast at $1,623,612,925, and the highest TSHA revenue forecast at $1,640,013,056. On average, 2 Wall Street analysts forecast TSHA's revenue for 2026 to be $1,640,013,056, with the lowest TSHA revenue forecast at $1,640,013,056, and the highest TSHA revenue forecast at $1,640,013,056.
In 2027, TSHA is forecast to generate $1,656,413,187 in revenue, with the lowest revenue forecast at $1,656,413,187 and the highest revenue forecast at $1,656,413,187.